Skip to main content
Erschienen in: Pediatric Cardiology 6/2008

01.11.2008 | Original Article

Extemporaneous Suspension of Propafenone: Attending Lack of Pediatric Formulations in Mexico

verfasst von: Hugo Juárez Olguín, Carmen Flores Pérez, Blanca Ramírez Mendiola, Rafael Coria Jiménez, Eunice Sandoval Ramírez, Janett Flores Pérez

Erschienen in: Pediatric Cardiology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Background Physicians have frequently encountered difficulties when prescribing drugs not available in doses suitable for pediatric age groups. Furthermore, children have difficulty swallowing tablets. This study aimed to determine the stability of an oral propafenone suspension made from commercial tablets with a syrup vehicle and to establish its reliable use with children. Methods An extemporaneous suspension of propafenone 1.5 mg/ml was prepared with commercial tablets. Its physicochemical and microbiologic stability was established by constant monitoring during 90 days at room temperature (15 ± 5°C) and at refrigeration (3–5°C). Plasma levels of propafenona were measured in two children with supraventricular tachycardia at steady state. Results The suspension was stable, maintaining its original physicochemical and microbiologic properties. Moreover, no apparent changes in color or odor were observed. Plasma levels of propafenone in patients demonstrated therapeutic concentrations after they had taken the suspension, with no unwanted outcome. Conclusions The conservation of both physicochemical and microbiologic stability of the suspension represents an option for the administration of propafenone to children.
Literatur
1.
Zurück zum Zitat Barnes S, Shields B, Bonney W et al (2004) The pediatric cardiology pharmacopoeia: 2004 update. Pediatr Cardiol 25:623–646PubMedCrossRef Barnes S, Shields B, Bonney W et al (2004) The pediatric cardiology pharmacopoeia: 2004 update. Pediatr Cardiol 25:623–646PubMedCrossRef
2.
Zurück zum Zitat Bink-Boelkens MT (2000) Pharmacologic management of arrhythmias. Pediatr Cardiol 21:508–515PubMedCrossRef Bink-Boelkens MT (2000) Pharmacologic management of arrhythmias. Pediatr Cardiol 21:508–515PubMedCrossRef
3.
Zurück zum Zitat Capucci A, Villani GQ, Aschieri D et al (1999) Safety of oral propafenone in the conversion of recent-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 68:187–196PubMedCrossRef Capucci A, Villani GQ, Aschieri D et al (1999) Safety of oral propafenone in the conversion of recent-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 68:187–196PubMedCrossRef
4.
Zurück zum Zitat Celiker A, Ozer S, Ozme S et al (1992) Experience with propafenone for the treatment of cardiac arrhythmias in children. Turc J Pediatr 32:85–92 Celiker A, Ozer S, Ozme S et al (1992) Experience with propafenone for the treatment of cardiac arrhythmias in children. Turc J Pediatr 32:85–92
5.
Zurück zum Zitat Flores Pérez C, Juárez Olguín H, Flores Pérez J et al (2005) A simple method to measure plasma levels of propafenone with fluorescence detection. Chromatographia 62:373–377CrossRef Flores Pérez C, Juárez Olguín H, Flores Pérez J et al (2005) A simple method to measure plasma levels of propafenone with fluorescence detection. Chromatographia 62:373–377CrossRef
6.
Zurück zum Zitat Funck-Brentano C, Kroemer HK, Lee JT et al (1995) Propafenone. N Engl J Med 322:518–525 Funck-Brentano C, Kroemer HK, Lee JT et al (1995) Propafenone. N Engl J Med 322:518–525
7.
Zurück zum Zitat Haefeli EW, Vozeh S, Ha HR et al (1990) Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 48:245–254PubMedCrossRef Haefeli EW, Vozeh S, Ha HR et al (1990) Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 48:245–254PubMedCrossRef
8.
Zurück zum Zitat Janousek J, Paul T (1998) Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 81:1121–1124PubMedCrossRef Janousek J, Paul T (1998) Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 81:1121–1124PubMedCrossRef
9.
Zurück zum Zitat Johnson CE, Streetman DD (2002) Stability of oral suspensions of ursodiol made from tablets. Am J Health Syst Pharm 59:361–363PubMed Johnson CE, Streetman DD (2002) Stability of oral suspensions of ursodiol made from tablets. Am J Health Syst Pharm 59:361–363PubMed
10.
Zurück zum Zitat Juárez Olguín H, Flores Pérez J, Lares Asseff I et al (2004) Medication related services in a Mexican pediatric hospital. Am J Health-Syst Pharm 61:2311–2312PubMed Juárez Olguín H, Flores Pérez J, Lares Asseff I et al (2004) Medication related services in a Mexican pediatric hospital. Am J Health-Syst Pharm 61:2311–2312PubMed
11.
Zurück zum Zitat Juárez Olguín H, Flores Pérez C, Flores Pérez J et al (2006) Bioavailability of an extemporaneous suspension of propafenone made from tablets. Biopharm Drug Dispos 27:241–245CrossRef Juárez Olguín H, Flores Pérez C, Flores Pérez J et al (2006) Bioavailability of an extemporaneous suspension of propafenone made from tablets. Biopharm Drug Dispos 27:241–245CrossRef
12.
Zurück zum Zitat Lares Asseff I, Juárez Olguín H, Gomez-Zamarroni A et al (1993) La unidad de farmacología clínica: Un recurso para la enseñanza y la asistencia farmacológica. Acta Pediatr Mex 14:138–143 Lares Asseff I, Juárez Olguín H, Gomez-Zamarroni A et al (1993) La unidad de farmacología clínica: Un recurso para la enseñanza y la asistencia farmacológica. Acta Pediatr Mex 14:138–143
13.
Zurück zum Zitat Mehvar R, Brocks DR, Vakily M (2002) Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet 41:533–558PubMedCrossRef Mehvar R, Brocks DR, Vakily M (2002) Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet 41:533–558PubMedCrossRef
14.
Zurück zum Zitat Nahata MC (1999) Lack of pediatric drug formulations. Pediatrics 104:607–609PubMed Nahata MC (1999) Lack of pediatric drug formulations. Pediatrics 104:607–609PubMed
15.
Zurück zum Zitat Rodríguez Pérez R, Barragán Mejía MG, Castilla Serna L (1992) Paquest version 1.0 Biomedical Software Developed S. de R.L. de C.V., México Rodríguez Pérez R, Barragán Mejía MG, Castilla Serna L (1992) Paquest version 1.0 Biomedical Software Developed S. de R.L. de C.V., México
16.
Zurück zum Zitat Rodríguiez R et al (2005) Vadémecum académico de medicamentos, 4th edn. McGraw-Hill Interamericana, México, D.F., pp 687–688 Rodríguiez R et al (2005) Vadémecum académico de medicamentos, 4th edn. McGraw-Hill Interamericana, México, D.F., pp 687–688
17.
Zurück zum Zitat Sasaki S, Kuomi S, Sato R et al (1998) Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. Gen Pharmacol 31:589–591PubMedCrossRef Sasaki S, Kuomi S, Sato R et al (1998) Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. Gen Pharmacol 31:589–591PubMedCrossRef
18.
Zurück zum Zitat VandenBussche HL, Jonhson CE, Fontana EM et al (1999) Stability of levofloxasin in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 56:2316–2318PubMed VandenBussche HL, Jonhson CE, Fontana EM et al (1999) Stability of levofloxasin in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 56:2316–2318PubMed
19.
Zurück zum Zitat Verbesselt R, Tjandramaga TB, de Schepper PJ (1991) High-performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid-phase column extraction. Ther Drug Monit 13:157–165PubMedCrossRef Verbesselt R, Tjandramaga TB, de Schepper PJ (1991) High-performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid-phase column extraction. Ther Drug Monit 13:157–165PubMedCrossRef
Metadaten
Titel
Extemporaneous Suspension of Propafenone: Attending Lack of Pediatric Formulations in Mexico
verfasst von
Hugo Juárez Olguín
Carmen Flores Pérez
Blanca Ramírez Mendiola
Rafael Coria Jiménez
Eunice Sandoval Ramírez
Janett Flores Pérez
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 6/2008
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-008-9257-5

Weitere Artikel der Ausgabe 6/2008

Pediatric Cardiology 6/2008 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.